{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T11:24:34Z","timestamp":1794482674317,"version":"4.9.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.vaccine.2020.01.038","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T03:37:57Z","timestamp":1581046677000},"page":"2396-2405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Deletion of major porins from meningococcal outer membrane vesicle vaccines enhances reactivity against heterologous serogroup B Neisseria meningitidis strains"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6578-1130","authenticated-orcid":false,"given":"Kathryn A.","family":"Matthias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Reveille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristie L.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann E.","family":"Jerse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamei S.","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret C.","family":"Bash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.01.038_b0005","unstructured":"Prevention UCfDCa. Enhanced Meningococcal Disease Surveillance Report, 2017. 2018."},{"key":"10.1016\/j.vaccine.2020.01.038_b0010","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/infdis\/126.5.514","article-title":"Immunologic response of man to group B meningococcal polysaccharide vaccines","volume":"126","author":"Wyle","year":"1972","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.038_b0015","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.4049\/jimmunol.138.12.4402","article-title":"IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues","volume":"138","author":"Finne","year":"1987","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2020.01.038_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.micres.2014.09.006","article-title":"Methods of isolation and purification of outer membrane vesicles from Gram-negative bacteria","volume":"170","author":"Klimentov\u00e1","year":"2015","journal-title":"Microbiol Res"},{"key":"10.1016\/j.vaccine.2020.01.038_b0025","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2018.00783","article-title":"Outer Membrane Vesicles: Current Status and Future Direction of These Novel Vaccine Adjuvants","volume":"9","author":"Tan","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2020.01.038_b0030","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/biot.201400395","article-title":"Outer membrane vesicles as platform vaccine technology","volume":"10","author":"van der Pol","year":"2015","journal-title":"Biotechnol J"},{"key":"10.1016\/j.vaccine.2020.01.038_b0035","series-title":"Bacterial Vaccines","first-page":"228","article-title":"Neisseria meningitidis Vaccines","author":"Frasch","year":"2003"},{"key":"10.1016\/j.vaccine.2020.01.038_b0040","doi-asserted-by":"crossref","first-page":"B117","DOI":"10.1016\/j.vaccine.2009.04.066","article-title":"Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease","volume":"27S","author":"Granoff","year":"2009","journal-title":"Vaccine"},{"issue":"S2","key":"10.1016\/j.vaccine.2020.01.038_b0045","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1086\/648966","article-title":"Review of Meningococcal Group B Vaccines","volume":"50","author":"Granoff","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.038_b0050","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1080\/21645515.2017.1381810","article-title":"Impact of meningococcal group B OMV vaccines, beyond their brief","volume":"14","author":"Petousis-Harris","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.01.038_b0055","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/mmi.13747","article-title":"Heterogeneity in non-epitope loop sequence and outer membrane protein complexes alters antibody binding to the major porin protein PorB in serogroup B Neisseria meningitidis","volume":"105","author":"Matthias","year":"2017","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.vaccine.2020.01.038_b0060","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1128\/iai.62.6.2432-2439.1994","article-title":"Expression of large amounts of Neisserial porin protein in Escherichia coli and refolding of the proteins into native trimers","volume":"62","author":"Qi","year":"1994","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.01.038_b0065","first-page":"67","article-title":"Production, characterization and control of MenB-vaccine \u201cFolkehelsa\u201d: an outer membrane vesicle vaccine against group B meningococcal disease","volume":"14","author":"Fredriksen","year":"1991","journal-title":"NIPH Ann"},{"key":"10.1016\/j.vaccine.2020.01.038_b0070","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1128\/jb.154.1.269-277.1983","article-title":"Morphological Heterogeneity Among Salmonella Lipopolysaccharide Chemotypes in Silver-Stained Polyacrylamide Gels","volume":"154","author":"Hitchcock","year":"1983","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2020.01.038_b0075","doi-asserted-by":"crossref","DOI":"10.1093\/femspd\/ftx033","article-title":"Novel approaches to Neisseria meningitidis vaccine design","volume":"75","author":"Christodoulides","year":"2017","journal-title":"Pathog Dis."},{"key":"10.1016\/j.vaccine.2020.01.038_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0022-1759(84)90080-2","article-title":"Use of a zwitterionic detergent for the restoration of the antibody-binding capacity of electroblotted meningococcal outer membrane proteins","volume":"67","author":"Mandrell","year":"1984","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2020.01.038_b0085","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0022-1759(88)90381-X","article-title":"Restoration of antibody binding to blotted meningococcal outer membrane proteins using various detergents","volume":"113","author":"Wedege","year":"1988","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2020.01.038_b0090","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jama.281.16.1520","article-title":"Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile","volume":"281","author":"Tappero","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2020.01.038_b0095","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1128\/IAI.00411-07","article-title":"Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis","volume":"75","author":"Weynants","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.01.038_b0100","first-page":"195","article-title":"Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba","volume":"14","author":"Sierra","year":"1991","journal-title":"NIPH Ann"},{"key":"10.1016\/j.vaccine.2020.01.038_b0105","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0140-6736(92)93086-3","article-title":"Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo Brazil","volume":"340","author":"de Moraes","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.01.038_b0110","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","article-title":"Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway","volume":"338","author":"Bjune","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2020.01.038_b0115","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1473-3099(11)70027-5","article-title":"From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak","volume":"11","author":"Caron","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.038_b0120","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/01.inf.0000258697.05341.2c","article-title":"New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16\u201324 months","volume":"26","author":"Wong","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.01.038_b0125","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1128\/CVI.00094-07","article-title":"Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines","volume":"14","author":"Sandbu","year":"2007","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2020.01.038_b0130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1128\/CVI.00230-06","article-title":"Immunogenicity and safety of three doses of a bivalent (B:4:P1.19,15 and B:4:P1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents","volume":"14","author":"Boutriau","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2020.01.038_b0135","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1016\/S0264-410X(99)00044-4","article-title":"Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins","volume":"17","author":"Cartwright","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.038_b0140","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/S0264-410X(99)00423-5","article-title":"Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2\u20133 and 7\u20138 years of age","volume":"18","author":"de Kleijn","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.038_b0145","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1086\/320993","article-title":"Prevention of meningococcal serogoup B infections in children: a protein-based vaccine induces immunologic memory","volume":"184","author":"de Kleijn","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.038_b0150","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/0264-410X(96)00001-1","article-title":"Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine","volume":"14","author":"Peeters","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.038_b0155","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1128\/iai.64.7.2745-2751.1996","article-title":"Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine","volume":"64","author":"van der Voort","year":"1996","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.01.038_b0160","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1128\/IAI.01108-08","article-title":"Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response","volume":"77","author":"Weynants","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.01.038_b0165","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1128\/IAI.70.7.3621-3626.2002","article-title":"Neisseria lactamica protects against experimental meningococcal infection","volume":"70","author":"Oliver","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.01.038_b0170","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1128\/CVI.00118-09","article-title":"Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles","volume":"16","author":"Gorringe","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2020.01.038_b0175","series-title":"16th International Pathogenic Neisseria Conference Rotterdam, The Netherlands","article-title":"Genetic modifications of three meningococcal group B multivalent vaccine strains","author":"Donets","year":"2008"},{"key":"10.1016\/j.vaccine.2020.01.038_b0180","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CVI.00403-08","article-title":"Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2","volume":"16","author":"Koeberling","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2020.01.038_b0185","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1086\/589308","article-title":"Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin","volume":"198","author":"Koeberling","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.038_b0190","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1016\/j.vaccine.2016.05.049","article-title":"Improving the immunogenicity of a trivalent Neisseria meningitidis native outer membrane vesicle vaccine by genetic modification","volume":"34","author":"Zhang","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.038_b0195","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1128\/IAI.01358-12","article-title":"Phase Variation of PorA, a Major Outer Membrane Protein, Mediates Escape of Bactericidal Antibodies by Neisseria meningitidis","volume":"81","author":"Tauseef","year":"2013","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.01.038_b0200","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1099\/jmm.0.05517-0","article-title":"Antigenic and\/or phase variation of PorA protein in non-subtypable Neisseria meningitidis strains isolated in Spain","volume":"53","author":"Alcal\u00e1","year":"2004","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.vaccine.2020.01.038_b0205","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1086\/367899","article-title":"Outbreak of meningococcal disease caused by PorA-deficient meningococci","volume":"187","author":"van der Ende","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.038_b0210","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.femsim.2004.03.005","article-title":"Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B\/C in neonatal mice","volume":"41","author":"Fukasawa","year":"2004","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.vaccine.2020.01.038_b0215","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1128\/CVI.00561-13","article-title":"Neisseria meningitidis native outer membrane vesicles containing different lipopolysaccharide glycoforms as adjuvants for meningococcal and nonmeningococcal antigens","volume":"21","author":"Nagaputra","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2020.01.038_b0220","first-page":"113","article-title":"Teasing apart structural determinants of 'toxicity' and 'adjuvanticity': implications for meningococcal vaccine development","volume":"10","author":"Steeghs","year":"2004","journal-title":"J Endotoxin Res"},{"key":"10.1016\/j.vaccine.2020.01.038_b0225","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0264-410X(02)00546-7","article-title":"Restored functional immunogenicity of purified meningococcal PorA by incorporation into liposomes","volume":"21","author":"Arigita","year":"2003","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20300530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20300530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:40:50Z","timestamp":1759401650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20300530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0264410X20300530"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.038","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deletion of major porins from meningococcal outer membrane vesicle vaccines enhances reactivity against heterologous serogroup B Neisseria meningitidis strains","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}